Clinical trial of cisplatinum (NSC 119875) in metastatic renal cell carcinoma.
Thirty-two patients with metastatic renal cell carcinoma were treated with cisplatinum, 100 mg./M2 at twenty-eight-day intervals. The drug was given intravenously after first assuring adequate hydration. Response could be determined in 23 patients. There were no partial or complete responses, although 1 patient had less than a 50 per cent reduction in pulmonary lesions and 7 patients had stabilization of their disease for periods ranging from three to seven months. It is concluded that the therapeutic value of cisplatinum in the treatment of advanced renal carcinoma is negligible when used as a single agent.